World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update Source: Eur Respir J, 57 (6) 2003300; 10.1183/13993003.03300-2020 Year: 2021
The future of drug-resistant tuberculosis treatment: learning from the past and the 2019 World Health Organization consolidated guidelines Source: Eur Respir J, 54 (4) 1901272; 10.1183/13993003.01272-2019 Year: 2019
World Health Organization treatment outcome definitions for tuberculosis: 2021 update Source: Eur Respir J, 58 (2) 2100804; 10.1183/13993003.00804-2021 Year: 2021
European Union standard for tuberculosis care on treatment of multidrug-resistant tuberculosis following new World Health Organization recommendations Source: Eur Respir J, 52 (5) 1801617; 10.1183/13993003.01617-2018 Year: 2018
World Health Organization guidance on the treatment of isoniazid-resistant tuberculosis Source: International Congress 2018 – New developments in tuberculosis Year: 2018
New treatment outcome definitions for drug-susceptible and drug-resistant tuberculosis: update from World Health Organization Source: Virtual Congress 2021 – Epidemiological aspects of tuberculosis Year: 2021
New definitions of pre-extensively and extensively drug-resistant tuberculosis: update from the World Health Organization Source: Eur Respir J, 57 (4) 2100361; 10.1183/13993003.00361-2021 Year: 2021
New definitions of extensively drug resistant tuberculosis: update from the World Health Organization Source: Virtual Congress 2021 – Advances in treatment and management of tuberculosis and nontuberculous mycobacterial disease Year: 2021
The World Health Organization standards for tuberculosis care and management Source: Eur Respir J, 51 (3) 1800098; 10.1183/13993003.00098-2018 Year: 2018
The 2011 update of the World Health Organization guidelines for the programmatic management of drug-resistant tuberculosis Source: Annual Congress 2011 - Multidrug-resistant tuberculosis Year: 2011
Applicability of the World Health Organization recommended new shorter regimen in a multidrug-resistant tuberculosis high burden country Source: Eur Respir J 2017; 49(1): 1601967; DOI: 10.1183/13993003.01967-2016 Year: 2017
The World Health Organization global aDSM database: generating evidence on the safety of new treatment regimens for drug-resistant tuberculosis Source: Eur Respir J, 51 (3) 1701643; 10.1183/13993003.01643-2017 Year: 2018
Reducing tuberculosis transmission: a consensus document from the World Health Organization Regional Office for Europe Source: Eur Respir J, 53 (6) 1900391; 10.1183/13993003.00391-2019 Year: 2019
Efficacy and safety of World Health Organization group 5 drugs for multidrug-resistant tuberculosis treatment Source: Eur Respir J 2015; 46: 1461-1470 Year: 2015
Incorporating therapeutic drug monitoring into the World Health Organization hierarchy of tuberculosis diagnostics Source: Eur Respir J 2016; 47:1867-1869 Year: 2016
The new World Health Organisation classification of lung cancer Source: International Congress 2016 – PG7 New guidelines for the classification and staging of lung cancer Year: 2016
European framework for tuberculosis control and elimination in countries with a low incidence: Recommendations of the World Health Organization (WHO), International Union Against Tuberculosis and Lung Disease (IUATLD) and Royal Netherlands Tuberculosis Source: Eur Respir J 2002; 19: 765-775 Year: 2002
The new World Health Organization classification of lung tumours Source: Eur Respir J 2001; 18: 1059-1068 Year: 2001
World Health Organization Collaborating Centre for Research and Training in Management of MDR-TB – curricula and methods Source: Eur Respir J 2005; 26: Suppl. 49, 191s Year: 2005
The World Health Organization actions on digital health for tuberculosis: perspectives for respiratory medicine Source: Virtual Congress 2021 – Digital health in respiratory medicine: opportunities for everyone Year: 2021